Glaukos's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Glaukos (GKOS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Glaukos vs Its Competitors
- TTM: Trailing 12-month revenue of 578M vs -M combined for its competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+46.0% annualized vs trailing 12 months).
- Scale: Glaukos ranks #17 of 246 companies by market capitalization in the Medical Equipment & Supplies industry, holding 1.2% of industry market cap.
- Peer revenue share: Glaukos accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.53M compares with $0.83M for the peer group (0.6x).
- Structure: Glaukos operates in the following segments: Development and Commercialization of Ophthalmic Therapies.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
GKOS Sales vs. its Competitors, Q3 2026
Glaukos generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Medical Equipment & Supplies industry grew revenue 14.8% year over year, combined, vs 59.0% for Glaukos. Glaukos's share of combined industry revenue moved from 0.13% to 0.18%, a gain of 0.05 percentage points.
Glaukos's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Glaukos Corp | No | Yes | Yes | No |
| Competitors combined (5) | ||||
| High-Confidence Competitors (5) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 100.00 % (8 of 8) | 87.50 % (7 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GKOS Stock Performance relative to its Competitors
GKOS Stock Performance relative to High-Confidence Competitors
GKOS Stock Performance relative to Similar-Size Competitors
GKOS Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Sight Sciences Inc | 282.9% | Outperformed |
| 2 | Novartis Ag | 282.9% | Outperformed |
| 3 | Abbvie Inc | 282.9% | Outperformed |
| 4 | Alcon inc | 282.9% | Outperformed |
| 5 | Eyepoint Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Glaukos's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Glaukos Corp
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Glaukos Corp |
14,511.41 | 578.35 |
 Abbvie Inc |
508,591.35 | 64,386.00 |
 Novartis Ag |
313,933.90 | 56,674.00 |
 Alcon inc |
36,143.21 | 10,401.00 |
 Sight Sciences Inc |
507.99 | 83.35 |
 Eyepoint Inc |
30.33 | 2.79 |
| SUBTOTAL | 873,718.20 | 132,125.49 |
Sources: Glaukos Corp's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Glaukos Corp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Glaukos's Competitors Named by the Company
Competitive relationships identified from Glaukos reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Alcon | Company report | 85% |
| Sight Sciences | Company report | 85% |
| AbbVie Inc. | Company report | 85% |
| Spyglass Pharma Inc | Company report | 85% |
| Lenz Therapeutics Inc | Company report | 85% |
| Ivantis Inc. | Company report | 85% |
| New World Medical | Company report | 85% |
| Eyepoint Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Aerie Pharmaceuticals Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Glaukos's named competitors require a Commercial License.
Methodology: relationships are extracted from Glaukos reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Glaukos's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Glaukos Corp | Development and Commercialization of Ophthalmic Therapies 100.00 % |
| Sight Sciences Inc | Surgical Glaucoma 96.66 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Glaukos's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Glaukos Corp | 14,511 | 528,661 | -155,209 |
| Abbvie Inc | 508,591 | 1,129,579 | 110,807 |
| Novartis Ag | 313,934 | 752,973 | 185,566 |
| Alcon inc | 36,143 | 416,040 | 39,200 |
| Sight Sciences Inc | 508 | 448,124 | -159,984 |
| Eyepoint Inc | 30 | 13,028 | -1,432,911 |
| PEERS TOTAL | 859,207 | 834,335 | 132,727 |
Glaukos's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Glaukos Corp | US 82.85 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Glaukos's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Glaukos's industry classification, broader than the peer set above. Market cap in millions of $.Glaukos ranks #17 of 218 companies by market capitalization in its industry, holding 1.23 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 600, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 154,357 | 13.55 % |
| 2 | Medtronic Plc | 124,064 | 10.89 % |
| 3 | Stryker Corp | 112,658 | 9.89 % |
| 4 | 3m Company | 91,075 | 8.00 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Becton Dickinson And Company | 1,234 | 5.2% |
| 7 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Dexcom Inc | 1,234 | 5.2% |
| 17 | Glaukos Corp | 13,975 | 1.23 % |
Market cap and industry share for the rest of Glaukos's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-10-30.
Glaukos's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 12 | Medline Inc | 27,652 | - |
| 13 | Steris Plc | 22,235 | -3.16 % |
| 14 | Zimmer Biomet Holdings Inc | 18,223 | -3.66 % |
| 15 | Carlisle Companies Incorporated | 15,241 | 12.49 % |
| 16 | Solventum Corporation | 1,234 | 12.3% |
| 17 | Glaukos Corp | 13,975 | 209.20 % |
| 18 | Smith and Nephew Plc | 1,234 | 12.3% |
| 19 | Penumbra Inc | 1,234 | 12.3% |
| 20 | Baxter International Inc | 1,234 | 12.3% |
| 21 | The Cooper Companies Inc | 1,234 | 12.3% |
| 22 | Globus Medical Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Glaukos's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-10-30. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Glaukos's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (320 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 77.32 % | 21.09 % (avg) | +56.2 pp |
| Operating Margin | -30.46 % | industry median | -30.5 pp |
| EBITDA Margin | -20.13 % | -4.06 % (avg) | -16.1 pp |
| Capital Intensity (Capex / Revenue) | 2.02 % | 6.78 % (avg) | -4.8 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Glaukos's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (320 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 36.5x | - |
| EV / EBITDA | - | 17.9x | - |
| P/B | 15.0x | 4.6x | +10.4x |
| Return on Equity | -24.91 % | industry aggregate | -40.56 % |
| Return on Invested Capital | -11.76 % | -3.89 % (avg) | -7.87 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Glaukos's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 39.21 % | 13.83 % | 30.73 % | 35.13 % | -3.79 % | 11.06 % | 22.07 % | 2.69 % |
| Operating Margin | -1.43 % | -7.17 % | -21.22 % | -11.18 % | -29.10 % | -40.97 % | -31.91 % | -50.69 % |
| Return on Invested Capital | -0.88 % | -4.11 % | -7.33 % | -2.29 % | -5.42 % | -9.38 % | -8.14 % | -12.35 % |
| P/E | - | - | 701.9x | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Glaukos's Strategic Group Map
Every company in Glaukos's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Glaukos is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Glaukos's trailing-12-month revenue growth of 23.3% and operating margin of -30.5% compares with an average of 20.1% growth and -22.4% margin across its 8 closest peers by combined growth, margin and ROIC -- Glaukos sits above that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Glaukos's BCG Growth-Share Matrix
Relative market share (vs Glaukos's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Glaukos falls in the Dog quadrant: relative market share of 0.09x vs its largest competitor, in an industry growing revenue 8.4% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Glaukos's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 600 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.02 % vs industry average 6.78 % (see Profitability & Cost Structure above) |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments. Supplier power and buyer power are not assessed here -- see Glaukos's dedicated Suppliers and Customers pages for concentration data; threat of substitutes has no systematic data source in this system and is not estimated.
Glaukos's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Glaukos falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Glaukos's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+46.0% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Operating margin 30.5 points below the industry median.
- Return on equity 40.6 points below the industry aggregate.
- Low relative market share vs the industry leader (0.09x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Glaukos's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Glaukos Corp | 1.12 | 4.90 | - |
| Abbvie Inc | 0.16 | 0.75 | - |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Alcon inc | 0.50 | 2.12 | 0.19 |
| Sight Sciences Inc | 5.67 | 7.06 | 0.69 |
| Eyepoint Inc | 4.89 | 6.71 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Glaukos's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Glaukos Corp | Q3 2026 | +59.0 % | - |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Alcon inc | Q4 2025 | +4.9 % | -3.7 % |
| Sight Sciences Inc | Q2 2026 | +25.8 % | - |
| Eyepoint Inc | Q2 2026 | -90.5 % | - |
| PEERS TOTAL | +9.2 % | +33.7 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Glaukos's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Glaukos Corp | Q3 2026 | +11.3 % | +27.2 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Alcon inc | Q4 2025 | +6.1 % | +14.8 % |
| Sight Sciences Inc | Q2 2026 | +0.7 % | -91.0 % |
| Eyepoint Inc | Q2 2026 | - | -1.6 % |
Glaukos's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Glaukos Corp | - | - | - |
| Abbvie Inc | 4.68% | 9.11% | - |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Alcon inc | 3.11% | 3.47% | 4.45% |
| Sight Sciences Inc | - | - | - |
| Eyepoint Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Glaukos's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Glaukos Corp | - | 25.09 |
| Abbvie Inc | 81.12 | 7.90 |
| Novartis Ag | 22.45 | 5.54 |
| Alcon inc | 36.79 | 3.47 |
| Sight Sciences Inc | - | 6.09 |
| Eyepoint Inc | - | 10.88 |
| PEERS AVERAGE | 42.09 | 6.61 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.